You are here
Home > Business > Health Care > Latest Research: 2018-2025 PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Report

Latest Research: 2018-2025 PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Report

Latest Report Available at Orbis research PARP (Poly ADP-Ribose Polymerase) Inhibitor Market provides pin-point analysis for changing competitive dynamics and a forward looking perspective on different factors driving or restraining industry growth.

Request sample copy of this report @  .

PARP means poly (adenosine diphosphate [ADP] -ribose) polymerase. It is a family of 17 enzymes that combine several (poly) units of ADP-ribose in a chain (the PAR chain) and transfers them to the target proteins. This helps to restore DNA when it is damaged. DNA can be damaged by many factors, including exposure to UV rays, radiation, some anti-cancer drugs or other substances in the environment. PARP inhibitors block an enzyme critical to the repair of single stranded breaks in DNA. Inhibition of this DNA repair enzyme can lead to cell death, particularly in cancer cells that carry deficiency in other DNA repair pathways.

PARP inhibitors play an effective maintenance role in current cancer-combating strategies with its superior effect to that of existing ovarian cancer treatment. Currently, Talazoparib and Veliparib are in Phase III clinical trials and Rucaparib, Olaparib and Niraparib are approved PARP drugs which are currently present in the market for ovarian cancer. PARP inhibitors improve progression-free survival in women with recurrent ovarian cancer, sensitive to platinum.

The U.S. is the major market of PARP inhibitor supported by PARPi for ovarian cancer in the market. The U.S. region is likely to experience further growth of PARP inhibitor market with upcoming PARP inhibitors and growing cases of cancer.

Browse Complete Report @ .

The global PARP inhibitor market is expected to grow in future due to increasing ageing population, rising cancer incidences, rise in health expenditure and improving economic conditions and vast unmet medical need. Key trends in this market include a combination of PARP and immuno therapy, increasing awareness, development of biomarkers and strong research and development efforts. However, there are some factors which can hinder the market growth including side effects, resistance to PARP inhibitors and regulatory challenges.

The report “Global PARP Inhibitor Market: Industry Analysis & Outlook (2018-2025)” by Koncept Analytics provides an extensive research and detailed analysis of the present market along with future outlook. The report discusses the major growth drivers and challenges of the market, covering the U.S. and Europe region along with the global market. The four major players: Tesaro Inc., Clovis Oncology, AstraZeneca and Abbvie Inc. are being profiled along with their key financials and strategies for growth.

Some points From TOC:

  1. Market Overview
    1.1 DNA Damage Response (DDR)
    1.2 DNA Repair Pathways
    1.3 PARP Inhibitor
    1.4 Inhibiting PARP Mechanism
    1.5 PARP for Cancer Treatment
    1.6 PARP Inhibitor Drugs
  2. Global Market Analysis
    2.1 Global PARP Inhibitor Market
    2.1.1 Global PARP Inhibitor Market Forecast by Value
    2.1.2 Global PARP Inhibitor Market Forecast by Cancer Type
    2.1.3 Global PARP Inhibitor Market Share Forecast by Cancer Type
    2.2 Global PARP Inhibitor Market by Drug Type
    2.2.1 Global Lynparza Market Forecast by Value
    2.2.2 Global Lynparza Market Forecast by Cancer Type
    2.2.3 Global Lynparza Market Forecast by Region
    2.2.4 Global Rubraca Market Forecast by Value
    2.2.5 Global Rubraca Market Forecast by Cancer Type
    2.2.6 Global Rubraca Ovarian Market Forecast by Line Therapy
    2.2.7 Global Zejula Market Forecast by Value
    2.2.8 Global Zejula Market Forecast by Cancer Type
    2.2.9 Global Zejula Ovarian Market Forecast by Line Therapy
  3. Regional Markets
    3.1 The U.S.
    3.1.1 The U.S. Ovarian Cancer Incidence Forecast
    3.1.2 The U.S. Ovarian PARP Market Forecast by Value
    3.1.3 The U.S. Ovarian Patients PARP Inhibitors Forecast by Drug
    3.1.4 The U.S. Ovarian Cancer Patients Receiving PARP by Line Therapy
    3.1.5 The U.S. Rubraca Market Forecast
    3.1.6 The U.S. Zejula Market Forecast
    3.2 European Union
    3.2.1 EU Ovarian Cancer Incidence Forecast
    3.2.2 EU Rubraca Market Forecast
    3.2.3 EU/ROW Zejula Market Forecast

Purchase a copy of PARP (Poly ADP-Ribose Polymerase) Inhibitor Market visit @   For more information contact       

  1. Market Dynamics
    4.1 Growth Drivers
    4.1.1 Rising Cancer Cases
    4.1.2 Rising Healthcare Expenditure
    4.1.3 Increased Ageing Population
    4.1.4 Increasing GDP Per Capita
    4.1.5 Vast Unmet Medical Need
    4.2 Key Trends & Developments
    4.2.1 Combinations of PARP Inhibitors and Immunotherapy
    4.2.2 Development of Ovarian Cancer Diagnosis Methods and Biomarkers
    4.2.3 Strong Research & Development Efforts by Companies
    4.2.4 Increasing Awareness of Early Diagnosis and Treatment of Disease
    4.3 Challenges
    4.3.1 Side Effects of PARP Inhibitors
    4.3.2 Resistance to PARP Inhibitors
    4.3.3 Regulatory Challenges

 For any enquires before buying, connect with us @

About Us:

Orbis Research ( is a single point aid for all your market research requirements. We have vast database of reports from the leading publishers and authors across the globe. We specialize in delivering customized reports as per the requirements of our clients. We have complete information about our publishers and hence are sure about the accuracy of the industries and verticals of their specialization. This helps our clients to map their needs and we produce the perfect required market research study for our clients.

Contact Information:

Hector Costello

Senior Manager – Client Engagements

4144N Central Expressway,

Suite 600, Dallas,

Texas – 75204, U.S.A.

Phone No.: +1 (214) 884-6817; +9164101019

Follow Us on LinkedIn:

Follow us on Twitter:

Like us on Facebook:

Leave a Reply